Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims reasonably align with core indications, mechanism, and key safety themes (infections risk, hypersensitivity) but include multiple inaccuracies or unsupported statements (pregnancy/lactation specifics, Category B labeling, certain infection specifics, malignancy risk, and broad treatment alternatives). Several clinically relevant label sections (contraindications, dosing specifics, pediatric safety, lactation details, and storage/handling) are not adequately addressed or misapplied.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication.
12.1
Cosentyx blocks the activity of interleukin-17A (IL-17A).
12.1
Cosentyx is used to treat psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
1.1, 1.2, 1.3
Cosentyx reduces inflammation.
12.2, 12.1
The pregnancy safety study did not provide conclusive evidence on the safety of Cosentyx during pregnancy.
8.1
It is not known whether Cosentyx is excreted in human milk.
8.2
Cosentyx can increase the risk of infections.
5.1
Cosentyx can increase the risk of upper respiratory tract infections.
5.1
Cosentyx can increase the risk of skin infections.
5.1
Cosentyx can cause allergic reactions.
5.2
Cosentyx can cause anaphylaxis.
5.2
Patients should discuss their reproductive plans with their healthcare provider before starting treatment with Cosentyx.
8.1
Unsupported Statements
Cosentyx is classified as a category B medication.
Labeling no longer uses FDA category A/B/C/D; pregnancy labeling is narrative (8.1) rather than category-based.
Category B means that it is not expected to cause harm to the fetus during pregnancy.
Labeling uses narrative risk summaries; the category concept is not used in current labeling.
The pregnancy safety study found that the rate of miscarriage was similar to that of the general population.
Label does not provide a definitively comparative miscarriage rate to general population; outcomes are described with background risk and limited data.
The pregnancy safety study found no significant differences in the rate of birth defects or other adverse pregnancy outcomes.
Label describes limited human data and inconclusive data in some domains; not a definitive statement of no differences.
A study published in the Journal of Clinical Rheumatology found that the levels of secukinumab in breast milk were low.
Not referenced or supported by the provided label text.
A study published in the Journal of Clinical Rheumatology found that the levels of secukinumab in breast milk were not likely to cause harm to the infant.
Not referenced or supported by the provided label text.
There have been reports of malignancies, including lymphoma, in patients treated with Cosentyx.
Label describes postmarketing experience with immune/other events but does not establish causality; wording here overstates the data.
It is not recommended for breastfeeding women.
Label provides limited lactation data and general considerations; not a blanket prohibition.
A study published in the Journal of Clinical Rheumatology found that the levels of secukinumab in breast milk were low.
Duplicate of above; not label-supported.
A study published in the Journal of Clinical Rheumatology found that the levels of secukinumab in breast milk were not likely to cause harm to the infant.
Duplicate of above; not label-supported.
There are various alternative treatments available for autoimmune diseases.
Not a safety-specific claim defined in the labeling; not enumerated in the provided sections.
Alternative treatments include non-biologic medications.
Not a safety-specific claim defined in the labeling.
Alternative treatments include lifestyle modifications.
Not a safety-specific claim defined in the labeling.
Contradictions
Low
AI Statement
UTIs are increased with Cosentyx.
Label Reference
5.1
Important Omissions
Explicit contraindications (e.g., active severe infections, active hepatitis B reactivation concerns) are not addressed in the claims.
Importance:
High
Dosing and administration details, including specific regimens, are not adequately covered by the claims.
Importance:
High
Pediatric safety and age-specific use details are not covered or are incompletely addressed.
Importance:
High
Storage and handling guidance is not addressed by the claims.
Importance:
Moderate
Explicit lactation data and guidance beyond 'not known' are not provided; breastfeeding considerations are not fully aligned with the label.
Importance:
Moderate
Clear discussion of boxed warnings (if applicable) and comprehensive adverse events beyond infections/hypersensitivity are not captured.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Core safety points (biologic mechanism, infection risk, hypersensitivity) align with labeling; inaccuracies largely pertain to pregnancy/lactation statements and non-labeled risk assertions, which could create confusion but do not indicate high immediate safety risk when interpreted conservatively.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Category B terminology and several pregnancy/lactation statements diverge from current labeling; missing/conflated contraindication and dosing details.
Suggested Improvement
Align pregnancy guidance with 8.1 and 8.2; replace Category B references with narrative risk summaries; explicitly state contraindications; incorporate dosing/administration specifics; address pediatric safety language; ensure UTIs risk not overstated; verify malignancy risk language to reflect labeling.